---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-075388"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T00:58:53.239842+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KALA BIO raises $12.5M in private placement; extends cash runway into Q4 2025

## Summary
- Gross proceeds of ~$12.5M from sale of 1,197,314 common shares at $5.85 and 9,393 Series H preferred shares at $585.00.
- Series H preferred convertible into 100 common shares each, subject to 9.99% beneficial ownership limitation.
- Cash runway extended into Q4 2025, including $9.1M remaining from CIRM award.
- Proceeds to fund clinical development of KPI-012 for persistent corneal epithelial defect.
- Private placement led by SR One with ADAR1 Capital and another investor; expected close June 28, 2024.

## SEC filing metadata
- accession: 0001104659-24-075388
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000110465924075388/0001104659-24-075388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000110465924075388/tm2418252d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-075388
- JSON: https://secwatch.observer/filing/0001104659-24-075388.json
- Plain text: https://secwatch.observer/filing/0001104659-24-075388.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.